Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amit Garg, professor and founding chairman of the department of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Garg explains why it’s an exciting time in hidradenitis suppurativa, and how clinicians are using existing therapies in innovative ways. Watch as he explains the impact of biologics on surgical therapies. Dr. Garg also outlines how deroofing can help treat drainage, one of the highest burdens patients with hidradenitis suppurativa experience.
If you want to read more about hidradenitis suppurativa, check out the following articles published in the Journal of Drugs in Dermatology:
Update on Hormonal Therapy in Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), a chronic inflammatory disorder of the apocrine-bearing skin, presents with deep seated inflamed nodules, abscesses, draining sinus tracts, and scarring with a profound impact on quality of life. In this review of Pubmed, EMBASE, and Cochrane Central databases, we focus on the role of hormonal therapies in the treatment of HS, including finasteride, cyproterone acetate, spironolactone, oral contraceptive pills, and metformin. A detailed search was conducted on these databases using key words like ‘hidradenitis suppurativa’, ‘acne inversa’, ‘antiandrogens’, and ‘hormonal therapy’.
Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report
Hidradenitis suppurativa (HS) is a morbid, recurrent skin condition that presents a major challenge to clinical therapy. Investigation into the pathogenesis of HS has implicated local and systemic pro-inflammatory cytokines, particularly TNF-α and IL-17A, as major determinants of disease progression and severity. This has ushered in a revolution in HS therapy with biologics targeting these cytokines. We report a case of a 36-year-old man with extensive and treatment-resistant Hurley Stage 3 HS. After undergoing numerous unsuccessful trials of topical, systemic, and biologic therapies, secukinumab therapy with 150 mg weekly injections was initiated. HS clinical response was seen after 20 weeks and was maintained for almost two years. Secukinumab 150 mg or 300 mg once weekly may be an effective and safe therapeutic option for moderate-to-severe chronic HS.
Ustekinumab in the Management of Hidradenitis Suppurativa: A Retrospective Study
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by the formation of recurrent abscesses in apocrine-bearing areas. In advanced stages, chronic inflammation leads to sinus tract formation and cicatrization.
Did you enjoy this video interview? Find more here.